VIDO-InterVac

Vaccine and Infectious Disease Organization -
International Vaccine Centre

Development of novel combination adjuvants

Project Leaders: George Mutwiri, Sylvia van den Hurk, Sam Attah-Poku, Volker GerdtsHeather L. Wilson 

Adjuvants are often added to antigens to modify or augment the effect of the antigen in vaccine formulations. Adjuvants function by stimulating the immune system to elicit better and more vigorous responses to the antigen, and can also be used to protect the antigen from untimely degradation, premature release or clearance.

As a limited number of adjuvants are licensed and available for use in vaccines, research is focused on developing novel adjuvants for use in human and animal vaccines, including combination adjuvants. Research is targeted at screening novel compounds, understanding mechanism of action, and evaluating the use in human and animal vaccine candidates.

Objectives:

  • Develop polyphosphazenes as vaccine adjuvants for human and animal vaccines
  • Investigate mechanisms of action of polyphosphazene adjuvants